Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/current-evidence-for-pharmacologic-reversal-using-direct-oral-MwDi8kMMPc
References (37)
-
H. Heidbuchel, P. Verhamme, M. Alings, M. Antz, H. Diener, W. Hacke, J. Oldgren, P. Sinnaeve, A. Camm, Paulus Kirchhof, Paulus Kirchhof (2015)
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 17 10
-
M. Sherwood, C. Nessel, A. Hellkamp, K. Mahaffey, J. Piccini, E. Suh, R. Becker, D. Singer, J. Halperin, G. Hankey, S. Berkowitz, K. Fox, M. Patel (2015)
Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial.Journal of the American College of Cardiology, 66 21
-
B. Samuelson, A. Cuker (2017)
Measurement and reversal of the direct oral anticoagulants.Blood reviews, 31 1
-
FDA approves Andexxa ® , the first and only antidote for the reversal of factor Xa inhibitors -
B. Myers, A. Webster (2017)
Heavy menstrual bleeding on Rivaroxaban ‐ Comparison with ApixabanBritish Journal of Haematology, 176
-
M. Crowther, G. Levy, Genmin Lu, J. Leeds, Joyce Lin, P. Pratikhya, P. Conley, S. Connolly, J. Curnutte (2014)
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal of Edoxaban-Induced Anticoagulation in Healthy Subjects By Andexanet Alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) InhibitorsBlood, 124
-
Genmin Lu, Stanley Hollenbach, D. Baker, Siusze Tan, A. Hutchaleelaha, J. Curnutte, P. Conley (2017)
Preclinical safety and efficacy of andexanet alfa in animal modelsJournal of Thrombosis and Haemostasis, 15
-
S. Glund, J. Stangier, J. Ryn, M. Schmohl, Viktoria Moschetti, W. Haazen, M. Smet, D. Gansser, S. Norris, B. Lang, P. Reilly, J. Kreuzer (2016)
Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib StudyClinical Pharmacokinetics, 56
-
Fast-tracks antidote to anticoagulant Pradaxa -
S. Glund, J. Stangier, M. Schmohl, D. Gansser, S. Norris, J. Ryn, B. Lang, S. Ramael, Viktoria Moschetti, F. Gruenenfelder, P. Reilly, J. Kreuzer (2015)
Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trialThe Lancet, 386
-
Shujuan Zhao, Hongwei Zhao, Xianpei Wang, Chuanyu Gao, Yuhua Qin, H. Cai, Boya Chen, Jingjing Cao (2017)
Factors influencing medication knowledge and beliefs on warfarin adherence among patients with atrial fibrillation in ChinaPatient preference and adherence, 11
-
F. Schiele, J. Ryn, K. Canada, Corey Newsome, E. Sepulveda, J. Park, H. Nar, T. Litzenburger (2013)
A specific antidote for dabigatran: functional and structural characterization.Blood, 121 18
-
SLBJX Bakhru (2013)
A synthetic small molecule which reverses over-dosage and bleeding by the new oral anticoagulantsCirculation., 128
-
K. Ghadimi, K. Dombrowski, J. Levy, I. Welsby (2016)
Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulationExpert Review of Hematology, 9
-
D. Adams (2017)
Idarucizumab for Dabigatran Reversal Full Cohort AnalysisJournal of Emergency Medicine, 53
-
S. Connolly, M. Crowther, J. Eikelboom, M. Gibson, J. Curnutte, J. Lawrence, Patrick Yue, M. Bronson, Genmin Lu, P. Conley, P. Verhamme, Jeannot Schmidt, S. Middeldorp, A. Cohen, J. Beyer-Westendorf, P. Albaladéjo, J. López-Sendón, A. Demchuk, D. Pallin, M. Concha, S. Goodman, J. Leeds, Sonia Souza, D. Siegal, E. Zotova, Brandi Meeks, S. Ahmad, J. Nakamya, T. Milling (2019)
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa InhibitorsThe New England Journal of Medicine, 380
-
J. Costin, J. Ansell, S. Bakhru, B. Laulicht, S. Steiner (2015)
The new oral anticoagulants: clinical use and reversal agent developmentISBT Science Series, 10
-
R. Makam, D. Hoaglin, D. McManus, Victoria Wang, J. Gore, F. Spencer, R. Pradhan, Hoang Tran, Hong Yu, R. Goldberg (2018)
Efficacy and safety of direct oral anticoagulants approved for cardiovascular indications: Systematic review and meta-analysisPLoS ONE, 13
-
J. Ansell, S. Zappe, Xuan Jiang, Lirong Chen, S. Steiner, B. Laulicht, S. Bakhru (2018)
A Novel Whole Blood Point-of-Care Coagulometer to Measure the Effect of Direct Oral Anticoagulants and HeparinsSeminars in Thrombosis and Hemostasis, 45
-
(2015)
Praxbind (idarucizumab) prescribing information: Food and Drug Administration (FDA) -
J. Ansell, S. Bakhru, B. Laulicht, S. Steiner, M. Grosso, K. Brown, V. Dishy, R. Noveck, J. Costin (2014)
Use of PER977 to reverse the anticoagulant effect of edoxaban.The New England journal of medicine, 371 22
-
D. Farmakis, P. Davlouros, G. Giamouzis, G. Giannakoulas, A. Pipilis, G. Tsivgoulis, J. Parissis (2018)
Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: Practical Considerations on the Choice of Agent and DosingCardiology, 140
-
M. Fang, A. Go, Yuchiao Chang, E. Hylek, Lori Henault, Nancy Jensvold, D. Singer (2007)
Death and disability from warfarin-associated intracranial and extracranial hemorrhages.The American journal of medicine, 120 8
-
S. Bakhru, B. Laulicht, Xuan Jiang, Lirong Chen, Deng Pan, M. Grosso, Y. Morishima, K. Brown, H. Masumoto, J. Costin, S. Steiner (2013)
Abstract 18809: PER977: A Synthetic Small Molecule Which Reverses Over-Dosage and Bleeding by the New Oral AnticoagulantsCirculation, 128
-
Genmin Lu, F. Deguzman, S. Hollenbach, M. Karbarz, K. Abe, Gail Lee, P. Luan, A. Hutchaleelaha, M. Inagaki, P. Conley, D. Phillips, U. Sinha (2013)
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor XaNature Medicine, 19
-
C. Pollack, P. Reilly, J. Ryn, J. Eikelboom, S. Glund, R. Bernstein, R. Dubiel, M. Huisman, E. Hylek, C. Kam, P. Kamphuisen, J. Kreuzer, J. Levy, G. Royle, F. Sellke, J. Stangier, T. Steiner, P. Verhamme, Bushi Wang, L. Young, J. Weitz (2017)
Idarucizumab for Dabigatran Reversal — Full Cohort AnalysisThe New England Journal of Medicine, 377
-
T. Dewald, R. Becker (2013)
The pharmacology of novel oral anticoagulantsJournal of Thrombosis and Thrombolysis, 37
-
J. Ansell, S. Bakhru, B. Laulicht, S. Steiner, M. Grosso, K. Brown, V. Dishy, H. Lanz, M. Mercuri, R. Noveck, J. Costin (2016)
Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxabanThrombosis and Haemostasis, 117
-
(2015)
approves Praxbind® the first reversal agent for the anticoagulant Pradaxa [media release -
C. Pollack, P. Reilly, J. Eikelboom, S. Glund, P. Verhamme, R. Bernstein, R. Dubiel, M. Huisman, E. Hylek, P. Kamphuisen, J. Kreuzer, J. Levy, F. Sellke, J. Stangier, T. Steiner, Bushi Wang, C. Kam, J. Weitz (2015)
Idarucizumab for Dabigatran Reversal.The New England journal of medicine, 373 6
-
S. Bakhru, B. Laulicht, X. Jiang, L. Chen, M. Grosso, Y. Morishima, K. Brown, H. Masumoto, J. Costin, S. Steiner (2013)
A synthetic small molecule antidote for anticoagulantsEuropean Heart Journal, 34
-
D. Siegal, J. Curnutte, S. Connolly, Genmin Lu, P. Conley, B. Wiens, Vandana Mathur, J. Castillo, M. Bronson, J. Leeds, Florie Mar, A. Gold, M. Crowther (2015)
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.The New England journal of medicine, 373 25
-
O. Grottke, M. Honickel, J. Ryn, H. Cate, R. Rossaint, H. Spronk (2015)
Idarucizumab, a Specific Dabigatran Reversal Agent, Reduces Blood Loss in a Porcine Model of Trauma With Dabigatran Anticoagulation.Journal of the American College of Cardiology, 66 13
-
C. Ruff, R. Giugliano, E. Braunwald, Elaine Hoffman, Naveen Deenadayalu, M. Ezekowitz, A. Camm, J. Weitz, Basil Lewis, A. Parkhomenko, T. Yamashita, E. Antman (2014)
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trialsThe Lancet, 383
-
J. Ansell, B. Laulicht, S. Bakhru, M. Hoffman, S. Steiner, J. Costin (2016)
Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin.Thrombosis research, 146
-
J. Weitz (2016)
Factor XI and factor XII as targets for new anticoagulants.Thrombosis research, 141 Suppl 2
-
S. Glund, J. Stangier, M. Schmohl, Viktoria Moschetti, W. Haazen, M. Smet, D. Gansser, S. Norris, B. Lang, P. Reilly (2014)
Idarucizumab, a Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Elderly and Renally Impaired SubjectsBlood, 124
- Publisher
- Springer Journals
- Copyright
- Copyright © Springer Nature Switzerland AG 2019
- Subject
- Medicine & Public Health; Cardiology; Pharmacotherapy; Pharmacology/Toxicology
- ISSN
- 1175-3277
- eISSN
- 1179-187X
- DOI
- 10.1007/s40256-019-00366-0
- Publisher site
- See Article on Publisher Site
Abstract
Direct oral anticoagulants are increasingly used in clinical practice and have addressed many of the issues related to vitamin K antagonists. However, the lack of reversal in life-threatening situations raises concerns regarding patient safety. Thus, current research is aimed at developing reversal agents that can safely neutralize the effects of anticoagulants. We present the design and mechanisms of action of and the animal models, clinical trials, and current evidence supporting the use of these emerging reversal agents. Idarucizumab is approved in many countries, and andexanet alfa has been approved by the US FDA, whereas others are in clinical trials. In view of the results of clinical studies to date, the problems of safety, price and accessibility remain. Therefore, these antidotes are a significant step towards improving the field of urgent and emergency reversal. From a practical perspective, post-market surveillance will be crucial to monitor the safety and effectiveness of these agents.
Journal
American Journal of Cardiovascular Drugs – Springer Journals
Published: Apr 22, 2020